Arcturus Therapeutics (ARCT) Tops Q4 EPS by 12c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($0.76), $0.12 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $2.97 million versus the consensus estimate of $2.36 million.

“Based on highly promising clinical data from our Phase 1/2 study and emerging mRNA vaccine immunological data, we are advancing ARCT-021 for further development in Phase 3. We are presently preparing to move forward a 5 µg single dose regimen, to be confirmed based on pending Phase 2 data. Our self-amplifying mRNA-based investigational vaccine may provide a differentiated clinical profile and characteristics that support widespread distribution across the globe. Our expectation is that successful protection from COVID-19 will require repeated vaccination of billions of individuals for years to come and that ARCT-021 will be re-dosable. We believe that a re-dosable, more easily distributable single shot mRNA vaccine would be a valuable option for many countries,” said Joseph Payne, President and CEO of Arcturus.

“In addition to advancing our vaccine franchise, we have made continued progress advancing our pipeline of promising liver and lung mRNA therapeutic candidates. After successfully beginning enrollment in the U.S. for our Phase 1b study for ARCT-810, a therapeutic candidate for Ornithine Transcarbamylase (OTC) Deficiency, we have now also received approval from Health Canada to enroll subjects. We look forward to obtaining clinical data this year,” concluded Mr. Payne.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
• Avangrid (AGR) Tops Q1 EPS by 19c